Latest Articles about BTX

Lower Loss at Geron - Analyst Blog

Zacks Equity Research — Thu, 14 Mar 2013 20:11:12 Z

Geron Corporation ( GERN ) posted a net loss of 10 cents per share in the fourth quarter of 2012, narrower than the Zacks Consensus Estimate of a loss of 14 cents and the year-ago loss of

Geron's Update on Stem Cell Assets - Analyst Blog

Zacks Equity Research — Fri, 11 Jan 2013 00:00:01 Z

Geron Corporation ( GERN ) announced that it has signed an Asset Contribution Agreement with BioTime, Inc. ( BTX ) and BioTime's recently formed subsidiary, BioTime Acquisition

Geron Scraps GRN1005, Cuts Jobs - Analyst Blog

Zacks Equity Research — Fri, 07 Dec 2012 03:18:01 Z

Geron Corporation ( GERN ) faced another pipeline setback recently with the company deciding to scrap the development of its phase II oncology candidate, GRN1005. GRN1005, which became a

Geron-BioTime Sign LOI - Analyst Blog

Zacks Equity Research — Fri, 16 Nov 2012 21:20:01 Z

A year after announcing its decision to exit stem cell therapy, Geron Corporation ( GERN ) announced that it has entered into a non-binding letter of intent (LOI) with BioTime, Inc. (

Geron Posts Narrower Loss - Analyst Blog

Zacks Equity Research — Wed, 31 Oct 2012 17:27:05 Z

Geron Corporation ( GERN ) posted a net loss of 13 cents per share in the third quarter of 2012, narrower than the Zacks Consensus Estimate of a loss of 14 cents and the year-ago loss of 16

Stem Cell Therapy May Prevent Heart Failure: 4 Companies to Watch

Kapitall — Thu, 17 Nov 2011 06:00:27 Z

( Written by Alexander Crawford. Data sourced from Finviz.) A stem cell treatment for heart disease from Australia’s biotech firm Mesoblast Ltd lowered the risk of heart attack or cardiac

30 Small Caps Snapped By Smart Money

Kapitall — Mon, 07 Mar 2011 20:58:50 Z

The following is a list of small cap stocks, with market caps between $300M-$500M. All of these companies have seen significant institutional and mutual fund buying over the last three